A Phase 2, Randomized, Stratified, Observer-Blind Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Older Adults
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Influenza vaccine quadrivalent Seqirus (Primary) ; Influenza virus vaccine; MF 59
- Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Seqirus
- 07 Dec 2021 Status changed from active, no longer recruiting to completed.
- 03 Jun 2021 Planned End Date changed from 23 May 2021 to 24 Jan 2022.
- 03 Jun 2021 Planned primary completion date changed from 23 May 2021 to 24 Jan 2024.